KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 106 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q3 2020. The put-call ratio across all filers is 0.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $441,337 | +0.3% | 25,408 | -18.7% | 0.00% | – |
Q2 2023 | $440,070 | +64.8% | 31,255 | +25.9% | 0.00% | – |
Q1 2023 | $267,052 | -19.9% | 24,819 | +11.5% | 0.00% | – |
Q4 2022 | $333,500 | +2.9% | 22,263 | -11.7% | 0.00% | – |
Q3 2022 | $324,000 | +90.6% | 25,209 | +43.6% | 0.00% | – |
Q2 2022 | $170,000 | -12.4% | 17,555 | -10.2% | 0.00% | – |
Q1 2022 | $194,000 | -14.2% | 19,545 | +1.3% | 0.00% | – |
Q4 2021 | $226,000 | +27.0% | 19,299 | +22.5% | 0.00% | – |
Q3 2021 | $178,000 | -14.8% | 15,757 | +5.0% | 0.00% | – |
Q2 2021 | $209,000 | -35.1% | 15,005 | -13.9% | 0.00% | – |
Q1 2021 | $322,000 | -65.0% | 17,423 | -66.6% | 0.00% | – |
Q4 2020 | $921,000 | +420.3% | 52,159 | +351.0% | 0.00% | – |
Q3 2020 | $177,000 | -74.0% | 11,566 | -56.8% | 0.00% | – |
Q2 2020 | $682,000 | +163.3% | 26,771 | +60.1% | 0.00% | – |
Q1 2020 | $259,000 | +27.0% | 16,719 | -9.5% | 0.00% | – |
Q4 2019 | $204,000 | +33.3% | 18,471 | +2.6% | 0.00% | – |
Q3 2019 | $153,000 | – | 18,011 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Fairmount Funds Management LLC | 2,474,561 | $42,983,125 | 5.17% |
Rubric Capital Management LP | 3,077,449 | $53,455,289 | 2.00% |
Parkman Healthcare Partners LLC | 509,810 | $8,855,400 | 1.62% |
TANG CAPITAL MANAGEMENT LLC | 600,000 | $10,422,000 | 1.47% |
AlphaCentric Advisors LLC | 110,000 | $1,910,700 | 1.08% |
Lion Point Capital, LP | 130,691 | $2,270,103 | 1.01% |
RICE HALL JAMES & ASSOCIATES, LLC | 650,366 | $11,296,857 | 0.72% |
ESSEX INVESTMENT MANAGEMENT CO LLC | 185,853 | $3,228,267 | 0.53% |
ADVISORY RESEARCH INC | 204,098 | $3,545,182 | 0.49% |
Jackson Creek Investment Advisors LLC | 65,607 | $1,140 | 0.48% |